Dermatology Products · LP-097
Silver sulfadiazine Cream
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-097Dermatology Products
- Generic identity
- Silver sulfadiazineCream
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-097
- Generic ingredient
- Silver sulfadiazine
- Dosage form
- Cream
- Proposed strength
- 1%
- Proposed pack
- Tube 20 g / 50 g; jar 250 g for hospital
- Portfolio category
- Dermatology Products
About Silver sulfadiazine
Silver sulfadiazine is a topical antimicrobial ingredient associated with specialist burn care. It combines silver with a sulfonamide and is supplied in some markets as a cream. Burn treatment requires assessment of depth, surface area, infection risk, pain and the need for referral. The presence of an antimicrobial does not by itself make a cream appropriate for every burn, and this entry does not rank it against modern dressings or establish first-line status.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinicians select wound management according to the burn and the patient, with repeated assessment of healing and infection. A hospital jar and a smaller tube may serve different care settings, but pack size does not define clinical eligibility. Silver sulfadiazine is not a substitute for prompt assessment of extensive, deep, chemical, electrical or critical-site burns. External monographs concern their own formulations and do not establish a Luang Pharma indication, treatment duration or burn-service protocol.
Important safety considerations
Important concerns include sulfonamide hypersensitivity, skin reactions and systemic effects when absorption occurs across extensive damaged skin. Blood-cell abnormalities and kidney or liver problems may require monitoring in higher-risk patients. Use near the end of pregnancy and in very young infants requires particular restriction under the applicable label because of sulfonamide-related neonatal risks. Consider glucose-6-phosphate dehydrogenase deficiency and stop for serious allergy. A complete contraindication assessment belongs to the treating burn team.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The catalogue records a cream with tube and hospital-jar presentations. The cream vehicle and product-specific microbiological controls require dossier confirmation. Container size does not establish suitability for repeated patient access or a particular in-use period.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Burn depth, extent, location, age, pregnancy status, allergies and comorbid disease should drive specialist review. Confirm the local authorized label and the care setting before product selection.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Silver sulfadiazine
- Dosage form / presentation
- Cream
- Catalogue strength
- 1%
- Catalogue pack
- Tube 20 g / 50 g; jar 250 g for hospital
- Portfolio category
- Dermatology Products
Layer 02
Unresolved product-specific fields
- Exact vehicle/excipient system, intended application site and formulation-specific instructions require controlled product documentation.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Silver sulfadiazine — ingredient/formulation referencegovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-097, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-097.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.